ALX ONCOLOGY HOLDINGS INC

Listed Company

ALXOCIK 0001810182NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-101.69M

Total Assets

$59.05M

Equity

$25.98M

Shares Out

134.56M

Op. Cash Flow

$-84.14M

ALXO$2.11+326.26% · past yearDBEQ Basic

Daily closing prices

Business

ALX Oncology Holdings Inc is a clinical-stage biotechnology company developing novel immunotherapies to treat cancer. Its lead product candidate, evorpacept, is a CD47 blocker designed for use in combination with anti-cancer antibodies to enhance immune-mediated tumor cell killing. The company's pipeline also includes ALX2004, an EGFR-targeted antibody-drug conjugate in Phase 1 development. Evorpacept is being evaluated in clinical trials across multiple cancer indications including HER2-positive breast cancer, gastric cancer, non-Hodgkin lymphoma, and multiple myeloma.

Summary from 10-K filed 2026-03-09

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	77	116	142	98	60
General and administrative	24	26	28	29	23
Impairment charge	3	—	—	—	—
Total operating expenses	104	142	170	127	84
Loss from operations	−104	−142	−170	−127	−84
Interest income	4	9	11	4	91,000
Interest expense	−2	−2	−2	−238,000	−13,000
Other income (expense), net	−36,000	−20,000	389,000	−22,000	−7,000
Loss before income taxes	−102	−135	−161	−123	−83
Income tax provision	0	0	0	−64,000	21,000
Net loss	−102	−135	−161	−123	−83
Net loss per share, basic	−1.9	−2.58	−3.74	−3.03	−2.07
Net loss per share, diluted	−1.9	−2.58	−3.74	−3.03	−2.07
Weighted-average shares of common stock used to compute net loss per share, basic	54	52	43	41	40
Weighted-average shares of common stock used to compute net loss per share, diluted	54	52	43	41	40

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	16	18	22	49	364
Short-term investments	28	110	160	217	—
Prepaid expenses and other current assets	6	7	6	5	3
Total current assets	51	134	189	271	367
Property and equipment, net	1	3	4	4	897,000
Long-term investments	3	4	35	17	—
Other assets	4	7	15	15	12
Total assets	59	148	243	306	380
Accounts payable	5	4	9	8	4
Payable and accrued liabilities due to related party	0	149,000	543,000	2	—
Term loan, current	5	435,000	—	—	—
Accrued expenses and other current liabilities	14	13	27	19	10
Total current liabilities	25	19	36	28	15
Term loan, non-current, net	5	9	10	9	—
Other non-current liabilities	4	6	7	5	2
Total liabilities	33	34	53	43	17
Commitments and contingencies (Note 13)	—	—	—	—	—
Common stock, $0.001 par value; 1,000,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 54,388,022 and 53,052,912 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively	54,000	53,000	50,000	41,000	41,000
Additional paid-in capital	749	734	676	590	565
Accumulated other comprehensive income	28,000	275,000	256,000	−845,000	—
Accumulated deficit	−723	−621	−486	−325	−202
Total stockholders equity	26	114	190	263	363
Total liabilities and stockholders equity	59	148	243	306	380

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−102	−135	−161	−123	−83
Stock-based compensation	13	27	26	24	14
Depreciation and amortization	706,000	872,000	836,000	342,000	51,000
Non-cash lease costs	2	2	1	1	685,000
Net accretion of discounts on investments	−1	−5	−6	−940,000	—
Accretion of term loan discount and issuance costs	280,000	265,000	250,000	44,000	—
Loss on disposal of fixed asset	—	10,000	—	—	—
Prepaid expenses and other current assets	658,000	−692,000	−1	−1	−2
Other assets	−686,000	7	1	750,000	−10
Accounts payable	421,000	−4	458,000	5	3
Payable and accrued liabilities due to related party	−149,000	−394,000	−1	20,000	1
Accrued expenses and other current liabilities	2	−13	11	7	3
Other non-current liabilities	−2	−2	−2	−977,000	−698,000
Net cash used in operating activities	−84	−122	−130	−89	−68
Purchase of investments	−52	−107	−247	−377	—
Maturities of investments	134	194	293	143	—
Purchase of property and equipment	−212,000	−447,000	−1	−1	−666,000
Net cash provided by investing activities	83	86	45	−235	−5
Proceeds from equity offerings, net of underwriter discounts ($3,795 thousand) and issuance costs ($567 thousand)	—	—	59	—	—
Proceeds from ATM offering, net of commissions	2	30	—	—	—
Proceeds from exercise of stock options under equity incentive plan	14,000	2	269,000	567,000	3
Proceeds from issuance of common stock under employee stock purchase plan	24,000	351,000	523,000	336,000	202,000
Principal payments on finance leases	−929,000	−827,000	−388,000	−388,000	−281,000
Principal payments on term loan	−435,000	—	—	—	—
Net cash provided by financing activities	362,000	31	59	10	2
Net (decrease) in cash, cash equivalents and restricted cash	−1	−5	−26	−315	−71
Cash paid for interest	1	1	1	103,000	11,000
Purchase of property and equipment in accounts payable and accrued expenses	962,000	1	1	2	237,000
Right-of-use asset (modified) acquired under finance leases	−182,000	1	3	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is ALX ONCOLOGY HOLDINGS INC's CIK number?

ALX ONCOLOGY HOLDINGS INC's SEC CIK number is 0001810182 (1810182). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find ALX ONCOLOGY HOLDINGS INC's SEC filings?

All of ALX ONCOLOGY HOLDINGS INC's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did ALX ONCOLOGY HOLDINGS INC last report earnings?

ALX ONCOLOGY HOLDINGS INC (ALXO) most recently filed an earnings 8-K with the SEC on May 8, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-213380). This is ALX ONCOLOGY HOLDINGS INC's most recent earnings filing of record — not a forecast of its next earnings date.

What is ALX ONCOLOGY HOLDINGS INC's most recent earnings 8-K?

ALX ONCOLOGY HOLDINGS INC's latest earnings 8-K (Item 2.02) was filed May 8, 2026 under accession 0001193125-26-213380. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View ALX ONCOLOGY HOLDINGS INC's latest earnings 8-K →
Look up any company's CIK number →